HHS Peptide Policy: The Six Peptides It Covers and What It Means for Patients

On October 28, 2026, HHS released its policy on compounding six peptides: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. HHS says it does not intend to take enforcement action against licensed pharmacies and physicians that compound them under set conditions while the FDA writes the permanent rules. None of the six is FDA approved, and the policy does not change that.

6 min read · Updated October 28, 2026

Dr. Jonathan Snipes, MDMedically reviewed by Dr. Jonathan Snipes, MD. Last reviewed October 28, 2026.

Quick Answer

HHS published its peptide policy. It covers six peptides: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. HHS says it does not intend to take enforcement action against licensed pharmacies that compound them under its conditions, including one peptide per product, until the FDA finishes its rules. None of the six is FDA approved. If you have a prescription, keep following it as written.

Rx Peps Direct tracks these developments because every peptide we offer is prescribed by a licensed provider after a $39 medical review and filled by a licensed U.S. compounding pharmacy. The rules that pharmacies follow decide what a provider can prescribe.

What did HHS publish?

HHS published a policy on six peptides. The Federal Register notice and the policy itself show:

  • Title: “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.”
  • Issued by the Office of the Secretary of Health and Human Services and signed by Secretary Robert F. Kennedy, Jr.
  • Filed for public inspection on October 28, 2026 and published in the Federal Register on October 30, 2026 (document 2026-22192).
  • It lasts until each peptide is addressed in a final rule on the list of substances 503A pharmacies may use, called the 503A bulks list.

It is the same policy that went to the White House for review on October 14 under the title “Interim Access Policy for Compounding Using Certain Peptides.” The review ended on October 27 as consistent with change, meaning the text was changed during review.

Which peptides are covered, and how?

Six peptides are covered, each only for the routes the policy names.

PeptideRoutes covered
BPC-157Subcutaneous or intramuscular injection, oral, topical
TB-500Subcutaneous or intramuscular injection
KPVTopical and oral
MOTS-cSubcutaneous or intramuscular injection
SemaxNasal
EpitalonSubcutaneous or intramuscular injection, in intermittent courses

Source: the policy’s Appendix A and Appendix B. The policy also names the salt form for each peptide, for example BPC-157 acetate.

These are the six peptides the FDA’s Pharmacy Compounding Advisory Committee recommended in July 2026. The seventh it reviewed, emideltide (DSIP), was voted down and is not covered. Rx Peps Direct prescribes all seven, including DSIP.

What conditions does the policy set?

The policy applies only when every one of its conditions is met:

  • One peptide per product. A compounded product may contain a single active ingredient from the list. Blends are not covered.
  • Tested ingredient from a registered source. The bulk peptide comes from an FDA-registered manufacturer and arrives with a certificate of analysis showing identity, purity, potency and testing for contaminants such as endotoxins, heavy metals and microbes.
  • A prescription for one patient. The product is compounded on a patient-specific prescription, under the other requirements of federal drug law.
  • Reporting. Pharmacies report serious adverse events and product quality problems to the FDA’s MedWatch program and to the states involved, and the patient’s label explains how to report a problem.
  • Label wording. The label states: “This is a compounded drug product. Not for resale.”
  • Oral forms need evidence. For an oral product, the pharmacy keeps documentation that the formulation is absorbed adequately in people.
  • Syringes only. The only device packaged with the product may be an FDA-cleared syringe.

What does the policy not do?

It does not approve anything, and it does not change the permanent list.

  • None of the six is FDA approved. The policy itself says compounded drugs are not FDA approved.
  • It does not add any peptide to the 503A bulks list. The FDA may propose adding some or all of them in future rulemaking.
  • It is not binding. The notice says it “does not establish any rights for any person and is not binding on HHS or the public.”
  • HHS may revisit it, in whole or in part, if a safety signal or product quality problem appears.
  • The FDA’s drug review staff recommended against listing each of the six, the policy notes. HHS gives its reasons for going ahead peptide by peptide in Appendix B.

Our BPC-157 FDA status page keeps a dated change log of each of these steps.

Why does HHS say it acted?

HHS says it wants to move patients away from research peptides. The policy says it will “discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers,” and that it gives patients “a more controlled alternative.” It also cites the July advisory committee meeting and data on how widely these peptides are used.

What does this mean if you already have a prescription?

Keep following your prescription as written.

  • Keep following the directions on your prescription label.
  • Questions about your own treatment belong with the provider who prescribed it. Rx Peps Direct patients can message their provider from the dashboard.
  • If you have a serious reaction, get medical care first, then tell your provider.

What does this mean if you are thinking about starting?

The safe route is the same: a prescription from a licensed provider, filled by a licensed pharmacy.

Products sold online as “research use only” are not made for people, and this policy does not cover them. See compounded peptides vs research peptides for the difference.

At Rx Peps Direct, a licensed provider reviews your health history before anything is prescribed. The medical review is $39, there is no subscription, and we serve patients in 28 states plus Washington, DC.

What happens next?

Three things to watch, all in official documents:

  1. Public comments. HHS takes comments for two weeks after the October 30 publication, on Docket HHS-OASH-2026-0496 at regulations.gov.
  2. Any revision. HHS says the most current version of the policy will be on its website.
  3. FDA rulemaking. A proposed rule to add any of these peptides to the 503A bulks list would appear in the Federal Register for public comment.

We will update this page when any of those happens.

Sources

Sources 1 and 2 are the official texts. These are the sources behind this page.

  1. U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A and Appendix B. October 2026. hhs.gov
  2. Federal Register. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice of availability, document 2026-22192, Docket HHS-OASH-2026-0496. Filed October 28, 2026; published October 30, 2026. federalregister.gov
  3. Office of Information and Regulatory Affairs, Office of Management and Budget. EO 12866 review, RIN 0910-ZD94. Received October 14, 2026; concluded October 27, 2026, consistent with change. reginfo.gov
  4. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov

Common questions about the HHS peptide policy

Which peptides does the HHS policy cover?
Six: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. Each is covered only for the routes the policy names. Semax is nasal only. KPV is topical and oral only. TB-500, MOTS-c and Epitalon are injection only.
Did HHS approve BPC-157?
No. BPC-157 is not FDA approved, and the policy says compounded drugs are not FDA approved. The policy is a statement that HHS does not intend to take enforcement action when its conditions are met. It also does not add BPC-157 to the 503A bulks list. See BPC-157 FDA status for the full position.
When does the policy start?
HHS filed the notice on October 28, 2026, and it was published in the Federal Register on October 30, 2026. Neither document gives a separate start date. The notice calls the policy a draft and takes public comments for two weeks after publication.
Does it cover peptide blends?
No. One of the policy’s conditions is that each compounded product contains a single active ingredient from its list. HHS says single-ingredient products make side effects easier to trace to one substance.
Is DSIP covered?
No. Emideltide (DSIP) is not on the list. It was the one peptide the FDA advisory committee voted against in July 2026.
Does this make research peptides safe?
No. The policy applies to licensed pharmacies and physicians compounding on a patient-specific prescription. HHS says its purpose is to steer patients away from research-use-only peptides made by foreign manufacturers.
Does this affect my current Rx Peps Direct order?
Keep following your prescription as written. If you have a question about your own treatment, message your provider from your dashboard.